Thalidomide-dexamethasone therapy was given in patients (o61 years) with previously untreated symptomatic multiple myeloma. The aim of this study was to assess the efficacy and toxicity of this combination as first-line therapy, and to determine its effect on stem cell collection and engraftment. During first-line therapy, thalidomide and dexamethasone were administered for 75 days (200 mg/day) and 3 months, respectively. The monthly dose of dexamethasone was 20 mg/m 2
Thalidomide-dexamethasone therapy was given in patients (o61 years) with previously untreated symptomatic multiple myeloma. The aim of this study was to assess the efficacy and toxicity of this combination as first-line therapy, and to determine its effect on stem cell collection and engraftment. During first-line therapy, thalidomide and dexamethasone were administered for 75 days (200 mg/day) and 3 months, respectively. The monthly dose of dexamethasone was 20 mg/m 2 /day for 4 days, with cycles repeated on days 9 to 12 and 17 to 20 on the first and the third month of therapy. After first-line therapy, a collection of peripheral blood stem cells (PBSC) was performed. Between May 2003 and September 2004, 60 patients were included. On an intent-to-treat basis, the overall response (Xpartial response) rate was 74%, including 24% of patients who obtained a complete remission. Grade 3-4 toxicities consisted of infections (12%), deep-vein thrombosis (3%), constipation (5%), and neuropathy (5%). A total of 58 patients (96%) proceeded to PBSC mobilisation and yielded a median number of 8 Â 10 6 CD34 þ cells/kg. and the use of autologous stem cell transplantation. [2] [3] [4] Bone marrow angiogenesis is increased in patients with MM and is a strong adverse prognostic indicator, correlating with the plasma cell labelling index and the disease stage. 5 In experimental models, thalidomide has inhibited angiogenesis and induced apoptosis of established neovasculature. 6 Recently, Kumar et al 7 demonstrated that in patients responding to thalidomide therapy, bone marrow angiogenesis decreased significantly.
Remarkable antimyeloma efficacy, reported to be about 30% with thalidomide alone 8, 9 and 50% with added dexamethasone 10, 11 in advanced and refractory MM, provided the basis for recent clinical trials aimed at investigating the role of these drugs as first-line therapy for patients with symptomatic MM. [12] [13] [14] The aim of this prospective, multicenter study was to evaluate the efficacy and toxicity of thalidomide and dexamethasone administered as primary therapy in patients with symptomatic MM, and to determine the effect of this combination therapy on stem cell collection and engraftment.
Patients and methods

Eligibility
Patients were eligible to enter the study if they were less than 61 years of age, were previously untreated and had a confirmed diagnosis of MM (Durie Salmon stage II and III). Patients were required to have bone marrow plasma cells X10% and measurable disease defined as serum monoclonal (M) protein X20 g/L and/or urine M protein X400 mg/24 h. Pregnant or nursing women were not eligible. Women of child bearing potential who were unwilling to use a dual method of contraception and men who were unwilling to use a condom were not eligible for the study.
Patients with Eastern Cooperative Oncology Group (ECOG) performance score of 4, chronic respiratory disease (DLco o60%), abnormal liver function (serum bilirubin level 445 mmol/l or an ALAT or ASAT level 44 Â normal), abnormal cardiac function (systolic ejection fraction o50%), serum creatinine level 4300 mmol/l, positive HIV test, prior concomitant malignancy (other than basal cell carcinoma of the skin, or in situ neoplasia of the cervix uterii), previous radiotherapy to 430% of marrow-bearing bone, and psychiatric disease were excluded. The study protocol was approved by the national medical ethical committee and a written informed consent was obtained from the patients.
First-line therapy and collection
Thalidomide (200 mg/day) and dexamethasone were administered for 75 days and 3 months, respectively. The monthly dose of dexamethasone was 20 mg/m 2 /day for 4 days, with cycles repeated on days 9 to 12 and 17 to 20 on the first and the third month of therapy.
If moderate side effects were encountered (grade 2 toxicity), the thalidomide dose was reduced by 50-100 mg decrements until an acceptable level was reached and maintained. For severe toxicity (4grade 2 toxicity), thalidomide was held and restarted using the aforementioned decrements after the side effect improvement. Baseline laboratory evaluation for risk factors for thrombosis (including antithrombin deficiency, protein C and protein S deficiencies, resistance to activated protein C, factor V Leiden mutation, prothrombin gene Gly20210A mutation, lupus anticoagulant, and antiphospholipid antibodies) was performed in all patients.
The first 13 patients who received dexamethasonethalidomide were not given prophylaxis of deep venous thrombosis (DVT). Among these first 13 patients, two (15.3%) had symptomatic DVT. 15 Because of the high rate of DVT observed in this first group, therapeutic doses of prophylactic anticoagulation with acenocoumarol were given for the remaining 47 patients (independently from the thrombophilic state of these patients). The addition of the anticoagulant resulted in no further DVT events. International normalized ratio of the prothrombin time (INR) range adopted for this group of patients was 2-3.
After first-line therapy, patients who proceeded to peripheral blood stem cells (PBSCs) collection received high-dose cyclophosphamide (HD-CY) (4 g/m 2 ) and granulocyte colony-stimulating factor (G-CSF) (5 mg/kg/day starting on day þ 3 from HD-CY and continuing until completion of the PBSC collection). PBSCs were harvested when CD34 þ cells in the blood were420/ml (usually between days þ 11 and 13 post-cyclophosphamide).
Autologous stem cell transplantation
Conditioning regimen consisted of melphalan (200 mg/m 2 ). Patients received G-CSF (5 mg/kg/day) from day 5 after stem cell transplantation and until neutrophil engraftment. Neutrophil engraftment was defined as the achievement of a sustained absolute neutrophil count of 500/ml. Two platelet engraftment levels were evaluated: a platelet count of 20 000/ml and a count of 50 000/ml. The date of platelet engraftment was defined as the first day to reach a sustained platelet count of 20 000/ml and a count of 50 000/ml, respectively, without platelet transfusions.
Response criteria
Criteria for defining complete remission (CR), partial remission (PR), or progressive disease were those previously reported by Blade`et al. 16 Patients who met previously reported criteria of no change or minimal response 16 were classified as having no response. Evaluation of response to thalidomide and dexamethasone was performed on days þ 30, þ 60, and þ 90 after the start of therapy.
Toxicity criteria
Adverse events were assessed monthly and graded according to the National Cancer Institute Common Toxicity Criteria (version 2).
Statistical analysis
An analysis of efficacy and toxicity was planned to be performed on the first 60 patients who could be evaluated. The primary efficacy variable was the proportion of patients who attained a response. Secondary end points of the study were toxicity, PBSC collection, and engraftment.
In the univariate analysis, an uncorrected w 2 -test or, when appropriate, Fisher exact test for categoric variables and Wilcoxon test for continuous variables were performed to identify the influence on collection and engraftment of different factors: age, sex, serum beta2-microglobulin, time between discontinuance of thalidomide and CY infusion, disease status at mobilization, number of days between cyclophosphamide administration and first collection, leucocyte count on the first day of leucapheresis, number of days of collection, time from diagnosis to stem cell infusion, disease status at transplantation, and number of stem cells infused.
Results
Patient characteristics
Between May 2003 and September 2004, 60 patients (32 female patients, 28 male patients) with previously untreated MM (Durie Salmon stage II and III) entered the study. Patient characteristics are summarized in Table 1 .
Treatment received
Of the patients, 52 (87%) completed the 75 days of thalidomide without discontinuation. Eight patients (13%) required thalidomide discontinuation because of 
Response
On an intent-to-treat basis, the overall response (Xpartial response) rate was 74%, including 24% of patients who obtained a complete remission. Six patients (10%) had a minor response, while the remaining 10 patients (16%) either failed to respond (n ¼ 7) or presented a disease progression (n ¼ 3). One patient in disease progression died with hyperviscosity syndrome 1 week after the end of thalidomide-dexamethasone therapy. Among responders, a decrease in serum M protein concentration X50% was registered in 75% of patients within the first month of therapy.
Toxicity
Dexamethasone-thalidomide therapy was well tolerated in most of the patients and generally did not require discontinuation. Only eight patients (13%) required thalidomide discontinuation because of toxicity (grade 42) (DVT in two patients, neuropathy in three patients, constipation in three patients).
Grade 3-4 toxicities consisted of constipation (5%), infections (12%), neuropathy (5%), and DVT (3%).
Among the first 13 patients, two (15.3%) had symptomatic DVT (documented by Doppler ultrasonography), of whom 1 had associated nonfatal pulmonary embolism. Thalidomide was stopped and anticoagulant treatment was promptly initiated after the diagnosis of DVT, with good clinical results. After one month of anticoagulant treatment, the two patients continued thalidomide-dexamethasone without evidence of progression of thrombo-embolic event.
The two patients who developed symptomatic DVT had a resistance to activated protein C (APC) in the absence of factor V Leiden mutation. In asymptomatic patients (n ¼ 11), thrombophilia study revealed the presence of a resistance to APC in one patient in the absence of factor V Leiden mutation. In this first group (n ¼ 13), a significant difference was seen in DVT between patients with APC resistance and those without APC resistance (2/3 vs 0/10; P ¼ 0.038). 15 Because of the high rate of DVT observed in the first group, therapeutic doses of prophylactic anticoagulation with acenocoumarol were given for the remaining 47 patients (independently from the thrombophilic state of these patients). We did not observe DVT in this group of patients (n ¼ 47). Thrombophilia study in this group (n ¼ 47) revealed the presence of a resistance to APC in the absence of factor V Leiden mutation in four patients, and a prothrombin gene Gly20210A mutation in one patient.
Stem cell collection data
Only two patients (3%) did not undergo PBSC mobilization because of refusal (n ¼ 1) or death (n ¼ 1). In total, fifty-eight patients (96%) proceeded to PBSC mobilization and yielded a median number of 8 Â 10 6 CD34 þ cells/kg (range, 4-32). The median number of aphereses was 2 (range, 1-4). The median number of CD34 cells collected was only affected by duration between thalidomide cessation and mobilization (P ¼ 0.032; Table 2 ). 
Haematopoietic reconstitution data
The median time from diagnosis of MM to transplantation was 4.5 months (range, 4-7). Times to engraftment are shown in Table 3 . A total of 58 patients were evaluable for graft function. On univariate analysis, the number of CD34 cells infused affected platelet engraftment (420 000/ml). No other factors influenced engraftment (Table 4) .
Discussion
Multiple studies have demonstrated the presence of increased bone marrow angiogenesis in MM. 17, 18 Thalidomide was initially studied for the treatment of advanced and refractory MM 8 because of its potential antiangiogenic effect. 19 Response rates of about 30% reported by Singhal et al 8 were confirmed by others groups. 9, [20] [21] [22] [23] Addition of dexamethasone to thalidomide in patients who failed to benefit from prior therapy, including both thalidomide and dexamethasone given as single agents, further increased responses, up to an overall response rate of 50-55%. 10, 11 These data suggested a synergy between thalidomide and dexamethasone and prompted several groups to explore this combination also in patients with previously untreated MM. [12] [13] [14] For many years, the standard treatment for young patients with MM has been a combination chemotherapy using non-alkylator-containing regimens such as vincristine, doxorubicin, and dexamethasone (VAD) for 3-5 months followed by high-dose therapy with autologous stem-cell transplantation. 2, 24 However, with use, the popularity of VAD has been tempered by the inconvenience and economic costs of a 4-day continuous infusion, the risk of catheter-related complications, and toxicity. 25 Obviously, availability of an effective, oral alternative to VAD, which obviates its disadvantages without interfering with stem cell collection, is likely to be of clinical relevance.
In our study, we observed on an intent-to-treat basis an overall response (Xpartial response) rate of 74%, including 24% of patients who obtained a complete remission. These results were consistent with those recently reported by three other groups using the same treatment combination in comparable groups of patients, [12] [13] [14] and did not differ from the rate of response expected by administering a more complex combination of VAD. 26 Only eight patients (13%) required thalidomide discontinuation because of toxicity (DVT in two patients, neuropathy in three patients, constipation in three patients). DVT emerged as the most troublesome adverse event associated with primary thalidomide-dexamethasone therapy. The first 13 patients who received dexamethasonethalidomide were not given prophylaxis of DVT. Among these first 13 patients, 2 (15.3%) had symptomatic DVT. 15 In accordance with a prior study, 27 we found that activated protein C resistance in the absence of factor V Leiden mutation was associated with an increased risk of thrombotic complications in patients with MM receiving first-line thalidomide-dexamethasone therapy. 15 Because of the high rate of DVT observed in the first group, therapeutic doses of prophylactic anticoagulation with acenocoumarol were given for the remaining 47 patients. INR range adopted for this group of patients was 2-3. No DVT was observed in this group (n ¼ 47). /kg. The total number of CD34 cells collected was only affected by duration between thalidomide cessation and mobilisation (P ¼ 0.032; Table 2 ). In our study, thalidomide discontinued approximately 3 weeks before attempted mobilization does not substantially affect peripheral stem cell collection. In contrast, other investigators 14 discontinued thalidomide the day before administration of HD-CY. In this study, 14 59 patients proceeded to PBSC mobilization and yielded a median number of 7.1 Â 10 6 /kg CD34 þ cells. Several factors have been identified as adversely affecting engraftment, including inadequate stem cell dose, increasing patient age, previous radiotherapy, and lack of growth factor use after infusion. [28] [29] [30] In a recent study, 31 early platelet engraftment of 20 000/ml was affected by previous thalidomide use. In line with other studies, we found on univariate analysis that the platelet engraftment (420 000/ml) was affected by the number of CD34 cells infused.
Our data demonstrate that thalidomide used for a limited time and discontinued approximately 3 weeks before attempted mobilization does not substantially affect peripheral stem cell mobilisation or engraftment.
In summary, the results of this prospective study show that the thalidomide-dexamethasone combination is an effective and relatively well tolerated induction regimen for previously untreated patients with MM. Based on the high rate of response and lack of stem cell injury, this combination might provide an oral alternative to VAD in preparation for autologous stem cell transplantation.
